Crizanlizumab

Drug Profile

Crizanlizumab

Alternative Names: SEG 101; Sel G1

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Selexys Pharmaceuticals
  • Developer Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sickle cell anaemia

Most Recent Events

  • 03 Dec 2016 Final efficacy data from the phase II SUSTAIN trial in Sickle cell anaemia released by Novartis
  • 21 Nov 2016 Selexys Pharmaceuticals has been acquired and merged into Novartis
  • 12 Apr 2016 Selexys Pharmaceuticals completes the phase II SUSTAIN trial for Sickle cell anaemia in USA, Brazil and Jamaica (NCT01895361) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top